Based on the knowledge of the shared signaling pathways between type I and type III IFNs and their restrictive effects in relation to various cell types, in this review, we evaluate the hypothesis that treatment of skin cancer with type III IFN will have minimal side effects compared with established treatments due to selective tumor targeting and the ability to generate both innate and adaptive immune responses. The gene discussed is SGCG; the disease is skin neoplasm.